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Background: A palette of copy number changes in a case of adult pilocytic astrocytoma analyzed by Array
Comparative Genomic Hybridization (aCGH) is presented. Pilocytic astrocytomas are specific gliomas that are benign
and biologically distinct and the molecular mechanisms responsible for their development remain unexplained. The
aCGH was performed using SurePrint G3 Human CGH microarrays 4 × 180 K (Agilent Technologies). To ascertain
whether some of the aberrations were of constitutive nature, we also analyzed the blood sample from the same
patient.
Results: The result of aCGH analysis demonstrated differences in the tumor tissue when compared to normal control
on the array and also to autologous DNA from patient’s blood. The total number of aberrations found in our case was
41 including 37 deletions and 4 amplifications. Whole chromosomal gains and losses were not observed. Collectively,
our results showed three deletions and one amplification at 1p, two deletions at 2q, two deletions at 4q, two deletion
at 5q, two deletions at 7p and two deletions at 7q; there were also three deletions at 8q, one deletion at 9p, one
deletion at 10p, three deletions and one amplification at 10q. Chromosome 11 showed two deletions at 11p, while
there was one deletion at 12p and one at 12q. Four deletions at 14q; two deletions at 15q, one amplification at 17q
and one deletion at 17q; one deletion at 18p, two deletions at 22q and finally one deletion at Xp and one deletion
and one amplification at Xq. Among the signaling pathways, olfactory transduction, Fc gamma R-mediated
phagocytosis and p53 signaling pathway showed significant enrichment ascertained by gene ontology (GO) analysis
using the DAVID software.
Conclusions: Our aCGH analysis is bringing subtle genomic alterations thus broadening genetic spectrum of adult
pilocytic astrocytoma in order to offer new molecular biomarkers that will help in diagnostics and therapeutic
decision-making.
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Astrocytic brain tumors are the most common primary
central nervous system neoplasms, but despite recent
advances in glioma genetics [1-3], the molecular mecha-
nisms behind their development and progression remain
largely unexplained. Different subtypes of gliomas differ
significantly in their age distribution, growth potential,* Correspondence: nina@mef.hr
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mas are classified according to their lineage of origin,
histology, behavior and prognosis into four WHO grades
[4,5]. Pilocytic astrocytomas (PA) most commonly de-
velops during the first two decades of life, but may also
develop in the third or fourth decade, with relatively few
arising in patients older than 50 years [6,7]. PA are clin-
ically, biologically, and histologically distinct from WHO
grade II-IV gliomas. PA typically shows benign clinical
behavior and malignant progression is extraordinarily
rare, describing PA as a benign tumor. Adult pilocytic
astrocytomas (PAs) are rare and usually have an aggres-
sive clinical course compared with pediatric patientsntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and lack of tumor specific immunohistochemical, cyto-
genetic and molecular markers, great effort has been put
into molecular and translational research of these tu-
mors in the last few years [10-14]. Another point for the
necessity of molecular characterization is the fact that
although the PAs can be cured with complete surgical
resection, clinical evidence demonstrate that unfavorable
anatomical location may impair complete resection and
lead to progression or recurrence.
Array comparative genomic hybridization (aCGH) is
a modern technique for detecting gene copy number
variation across the entire genome. It is a reliable and
sensitive method and has been widely used in genetic
profiling of different types of cancer as one of the main
characteristics of cancer diseases is genomic instability
[15,16]. We were interested to characterize unbalanced
genomic changes in our pilocytic astrocytoma patient
and offer potential candidate genes detected by aCGH
analysis. Until recently little was known about genetic
events that are involved in PA initiation and early de-
velopment. Few constant genetic findings reported are:
the association of neurofibromatosis type 1 (NF1) syn-
drome with an increased incidence of low-grade gli-
omas [1], mutations of KRAS activating MAPK pathway
in sporadic PA [17], mutations of BRAF, especially a
substitution called V600E, and constant chromosome
gains at 7q34 [18-22].
Here we present aCGH analysis of a case of adult pilo-
cytic astrocytoma.
Patient and methods
Pilocytic astrocytoma brain tumor was collected from the
Department of Neurosurgery, University Hospital “Sisters
of Charity”, Zagreb, Croatia. Autologous blood sample of
the same patient was also obtained. The patient had no
family history of brain tumors. The tumor tissue was fro-
zen in liquid nitrogen and transported to the laboratory,
where it was immediately transferred to −75°C. The per-
ipheral blood sample was collected in EDTA and proc-
essed immediately. Magnetic resonance imaging (MRI)
revealed that the astrocytic brain tumor was localized in
right frontoparietal region. During the operative proced-
ure the tumor was removed using a microneurosurgical
technique. On the basis of the pathohistological findings
diagnosis of pilocytic astrocytoma was established.
Ethical approval was received from the Ethical Commit-
tees Medical School University of Zagreb and University
Hospital “Sisters of Charity”, and the patient gave his in-
formed consent.
DNA extraction
Approximately 0.5 g of tumor tissue was homogenized
with 1 ml extraction buffer (10 mM Tris HCl, pH 8.0;0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl sulfate) and
incubated with proteinase K (100 μg/ml; Sigma, USA;
overnight at 37°C). Phenol chloroform extraction and
ethanol precipitation followed. Blood was used to extract
leukocyte DNA. Five ml of blood was lysed with 7 ml
distilled water and centrifuged (15 min/5000 g). The pel-
let was then processed as for DNA extraction from the
tissue samples. Samples were purified using PCR purifi-
cation kit (Qiagen). The concentrations were measured
by Nanodrop and the purity of DNA was determined.
Each DNA sample was analyzed on 1.5% agarose gel to
assess genomic DNA intactness and the average molecu-
lar weight.
aCGH
Array Comparative Genomic Hybridization (aCGH)
was performed using SurePrint G3 Human CGH mi-
croarrays 4 × 180 K (Agilent Technologies) following
the manufacturer’s instructions. Briefly, 1 μg of gen-
omic DNAs corresponding to either a human reference
control (Promega) or test samples were fragmented by
heating at 95°C for 10 minutes. Fragmented DNAs were
labeled with Cy3 (reference DNA) and Cy5 (test sam-
ples) fluorescent dUTP, respectively, using the SureTag
Complete Labeling Kit (Agilent Technologies). Purifica-
tion columns (Agilent) were used to remove the unincor-
porated nucleotides and dyes. The labeled samples along
with human Cot-1 DNA were added together and hybrid-
ized on the array slides. Hybridizations of labeled DNAs
to SurePrint G3 Human CGH Arrays (4 × 180 K) (Agilent
Technologies) were performed in a hybridization oven at
65°C at 20 rpm for 24 hours. The slide was scanned at
3 μm resolution on Agilent Microarray Scanner System
(Agilent Technologies). Agilent CytoGenomics software
(Agilent Technologies) was used to visualize, detect,
and analyze chromosomal patterns within the micro-
array profiles.
Case presentation
Our patient was a 42 years old male admitted to the
Department of Neurosurgery, University Hospital “Sestre
Milosrdnice” manifesting symptoms of raised intracranial
pressure including severe occipital headaches and nausea
caused by a brain tumor. The symptoms lasted for
10 months. The patient was without clinical NF1 or
NF2 and had no family history of brain tumors. Using
the magnetic resonance imaging (MRI) a tumor lesion
was found in the right anterior intraventricular region.
The well circumscribed tumor was located from the III
ventricle all the way to the foramen of Monro and cra-
nially to the corpus callosum. During the operative pro-
cedure the astrocytoma was maximally reduced using a
microneurosurgical technique. The surgical access route
was the interhemispheric transcallosal approach, passing
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ularly in the corpus of the right lateral ventricle. The
foramen of Monro was freed to the right and the com-
munication between right lateral ventricle and the third
ventricle was established. On the frozen and subsequent
permanent sections tumor was made of alternating areas
of densely and loosely packed fibrillary neoplastic cells
with long, hair-like cytoplasmic processes. Microcystic-
clear cell features (Figure 1A) and Rosenthal fibers
(Figure 1B) were also present. In some areas hyalinized
blood vessels and glomeruloid microvascular prolifera-
tion was also observed. Mitoses, anaplastic cells as well
as necrosis were not found. Immunohistochemically,
the tumor cells were strongly positive for glial fibrillary
acidic protein (GFAP). Neuropathological examination
revealed pilocytic astrocytoma and classified the tumor
into grade I according to the WHO criteria [23]. The
follow-up was 10 years without recurrence.
The result of aCGH analysis demonstrated differences
in the tumor tissue when compared to normal control
on the array. The total number of aberrations found in
our case was 56, among which deletions dominated.
Whole chromosomal gains and losses were not observed.
To ascertain whether some of the aberrations were of con-
stitutive nature, we also analyzed the blood sample from
the same patient compared to the reference DNA. DNA
obtained from blood comprised altogether 22 copy num-
ber changes of which there were 13 deletions and 9 ampli-
fications. The majority of changes (68%) from autologous
constitutive DNA were repeated in the belonging tumor
DNA (15/22). Four amplifications and 3 deletions were
exclusive for the blood DNA. The analyzed DNA from
pilocytic astrocytoma contained altogether 41 copy num-
ber alterations exclusively found in tumor, including 37
deletions and 4 amplifications. The observed major gen-
omic findings are detailed in Figure 2.
Collectively, our results showed three deletions and one
amplification at 1p, two deletions at 2q, two deletions atFigure 1 The tumor areas with microcystic-clear cell features were pr
predominantly in loosely arranged areas of tumor (B, 400 × HE).4q, two deletions at 5q, two deletions at 7p and two dele-
tions at 7q; there were also three deletions at 8q, one dele-
tion at 9p, one deletion at 10p, three deletions and one
amplification at 10q. Chromosome 11 showed two dele-
tions at 11p, while there was one deletion at 12p and one
at 12q. Four deletions at 14q; two deletions at 15q, one
amplification at 17q and one deletion at 17q; one deletion
at 18p, two deletions at 22q and finally one deletion at Xp
and one deletion and one amplification at Xq.
Annotated genes possibly involved in this tumor are
also presented in Figure 2. Pseudogenes and loci with
unknown gene function were excluded from the table.
In an effort to ascertain possible overrepresentation
of specific gene ontology (GO) terms among the genes
located within the regions showing altered DNA copy
numbers, we performed GO analysis using the DAVID
software. The GO terms related to the genes located
within the regions with altered copy number included
olfactory and sensory transduction, cognition, zinc finger
region, neurological system process, G-protein coupled re-
ceptor, DNA repair and proto-oncogene. Among the
signaling pathways, olfactory transduction, Fc gamma
R-mediated phagocytosis and p53 signaling pathway
showed significant enrichment (Figure 3).
To summarize the functions of candidate annotated
genes we found changes in chromosomal regions har-
boring genes whose products are transcription factors,
activators or repressors of transcription, translation fac-
tors, oncogenes, those involved in DNA repair, in cytoskel-
etal organization, development, chromatin remodeling,
apoptosis. There were also several microRNAs, kinases,
neurotransmitters, tumor suppressor genes and methyl-
transferases. Since the etiology of pilocytic astrocytoma
(PA) is associated to several major cellular signaling
pathways we investigated whether some of the anno-
tated genes belong to pathways specific to PA. We
found genes that are involved in Ras-Raf-MEK-ERK sig-
naling, p53 signaling, RB signaling, Wnt signaling.ominent (A, 200 × HE). Rosenthal fibers (arrow) were focally present,
Figure 2 The major genomic findings and annotated genes in adult pilocytic astrocytoma.
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Although the PAs are well circumscribed, benign and
show prolonged overall survival and high completeremission rates, some are surgically inaccessible, lead-
ing to chronic disease with recurrences. As technolo-
gies progress genetic profiles and molecular findings
Figure 3 Gene ontology (GO) analysis using the DAVID software. Role of the affected genes within the p53 signaling pathway.
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distinction of tumor subtypes. Molecular characteristics
are also being helpful in explaining the responses to
therapy [5].
In order to investigate genetic alterations in a patient
with pilocytic astrocytoma we performed aCGH ana-
lysis using DNA samples obtained from patient blood
and tumor. Array CGH compares genomic DNAs isolated
from test and reference samples that are differentially la-
beled with red (Cy5) and green (Cy3) fluorescent dyes and
competitively hybridized to known mapped segments of
human genomic DNA (eg, bacterial artificial chromo-
somes/P1-derived artificial [BAC/PAC] or oligonucleotide
probes) attached to a slide. There are several major advan-
tages to CGH arrays, including ease of implementation,
the ability to use archival samples, and the ability to detect
copy number changes at a higher resolution.
In our patient whole chromosomal gains and losses
were not observed which is in accordance with previous
findings [24], although some reports on whole chromo-
somal gains (chromosomes 5,7,8 [25-27]) and losses (chro-
mosomes 7, 8, 17 [5,28]) in PAs have been published. The
reported cytogenetic band abnormalities include gains of
1p, 2p, 4q-9q and 13q and losses on 1p, 9q, 12q and 19–
22 [5,25,26,29-32]. There are also reports on subtelomeric
gains at 7qter, 12qter, 13cen, 19pter, X/Yqter and duplica-
tion at 3pter, while subtelomeric deletions have been ob-
served at 8pter, 20pter and 21qter. It is interesting to note
that most PAs exhibit a normal karyotype [5,28,33,34].Nevertheless there are approximately 32% that show
chromosomal abnormalities. Moreover, the higher num-
ber of chromosomal abnormalities in PAs are associated
with older patients, while patients younger than 15 years
usually show single chromosomal abnormalities [5,32].
The situation found in our case of adult PA is confirming
this since we observed many copy number changes.
Our results also showed that some changes were simi-
lar to the reports, but some were unique for our patient.
The high number of copy number changes found in
our patient can also be indicative of the acquisition of
genomic instability of the tumor, especially since deleted
regions harbor genes involved in mismatch repair and
therefore the acquisition of genomic instability. Charac-
teristic behavior of PA indicates that they may be mo-
lecularly distinct glial neoplasms.
As far as annotated genes possibly involved in this
tumor are in question our results bring many candidates.
The roles of many of them are still unknown. Identifying
narrow regions with altered DNA copy number is an im-
portant finding in tumor genetics, as genes mapped in
these regions may represent potential candidate tumor
suppressor genes and oncogenes. The cytoband 17q11.2
holding the NF1 gene was not changed in our case which
is consistent to nowadays standpoint that NF1 abnormal-
ities are unique to NF1 associated PAs and are not ob-
served in sporadic tumors indicating that sporadic PAs
and the ones associated to neurofibromatosis 1 are mo-
lecularly distinct. The abnormalities involving molecular
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role in sporadic PAs [35,36]. The most common gen-
omic abnormalities found in sporadic PAs are BRAF
fusion genes. Changes involving BRAF seem to be very
frequent in sporadic PAs [20,22,37]. There are several
reported fusions, of which BRAFex9–KIAA1549ex16 is
the most common, followed by BRAFex9–KIAA1549ex15
and BRAFex11–KIAA1549ex16 [38]. Another BRAF fu-
sion is the one with FAM131B gene [21]. Our sample
showed 4 changes on chromosome 7, but the closest
cytobands were q33 and q36.1 leaving us to conclude
that BRAF changes were not involved in our PA case.
This is not an unusual finding since [9] report on only
20% of sporadic PA cases with BRAF–KIAA1549 fusion.
There is still the unanswered question on BRAF muta-
tional activation in our case.
Of interest is also that many of the annotated genes
have been found to be expressed in the human glioma
cell line GaMg [39].
Because pilocytic astrocytomas are clinically, biologic-
ally, and histologically distinct from WHO grade II-IV
gliomas [27], it is interesting to provide information on
genetic blueprint of those tumors. Common genetic
changes and tumor associated mutations found in higher
grade gliomas, p53, PDGF, p16 (CDKN2A), IDH1 and
IDH2 are rarely reported in PAs [1] which is consistent
to our results that also indicate lack of abnormalities in
loci where those genes reside. It is interesting to note
that genes SOCS3, HLA-DRalpha, HLA-DRB1, A2M,
HIPK2, MATN2, TIMP1, TIMP4, tenascin-R, FGFR1,
NTRK2, ErbB4, VEGF and VEGFR reported by other
authors [2,5,24] to be involved in PA were not found in
our patient.
Nevertheless, it is important to validate (verify) the in-
volvement of candidate genes in further studies that em-
ploy other methods of molecular biology.
To include intrinsic control is very important due to
the possibility of large scale copy number polymorph-
ism in the human genome [40]. Our findings demon-
strated that up to 68% of changes observed both in the
constitutive DNA were also present in the tumor tissue
as compared to unrelated normal reference. This could
be explained by copy number polymorphism specific
for the person, but it could also be an indication on
germline genetic predisposition.
Recently it was shown that age and location also mat-
ter in sporadic PA [4,35,41]. Recent data suggest that
pediatric and young adult gliomas arise from neurode-
velopmental defects that occur during specific develop-
mental windows. BRAF signaling has been shown to be
mandatory in the development of the cerebellum,
whereas NF1, or more upstream FGFR signaling, seems
important for diencephalic and midline development
[4]. Interestingly, we found copy number changes inregions that harbor developmental genes i.e. HOX genes,
oncomodulin, DAGLB, ZNF12,TRIM 37, MBTPS2,YY2.
Conclusions
Despite many recent advances on the molecular biology
of pilocytic astrocytoma, its molecular blueprint of de-
velopment and progression is still largely unexplained.
Our findings contribute to better understanding of hu-
man PA brain tumor genetic profile and suggest that
copy number alterations play important roles in PA eti-
ology. The findings may provide molecular biomarkers
that will help in diagnostics and therapeutic decision-
making.
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